Journal profile · HEMATOLOGY
Lancet Haematology
ISSN 2352-3026 · Lancet Publishing Group · ENGLAND
Lancet Haematology: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 19.41; hybrid open access; APC about USD 7,280; median 70 days to acceptance (77 articles, last 24 months); 177 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Lancet Haematology is published by Lancet Publishing Group and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Lymphoma Diagnosis and Treatment, Myeloproliferative Neoplasms: Diagnosis and Treatment and Acute Myeloid Leukemia Research, together about 25.6% of its articles. Its main subfields are Genetics and Hematology. (generated from OpenAlex topic counts and CAS ranking data)
The Lancet Haematology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The journal publishes original research, review, and opinion covering international issues, providing a clear, independent perspective about the clinical advances and practice-changing research shaping clinical haematology.The Lancet Haematology is dedicated to publishing original research that advocates change in, or illuminates, haematological clinical practice, including, but not limited to, the subjects of: haematology-oncology, red and white blood cell disorders, platelet disorders, stem cell transplantation and induced pluripotent stem cells, and transfusion medicine.
From the journal's Aims & Scope
Research area (LetPub): HEMATOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lymphoma Diagnosis and TreatmentMedicine9.9%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine8.2%
- Acute Myeloid Leukemia ResearchMedicine7.5%
- Hemoglobinopathies and Related DisordersMedicine6.1%
- Chronic Lymphocytic Leukemia ResearchMedicine6%
- Acute Lymphoblastic Leukemia researchMedicine5.9%
- CAR-T cell therapy researchMedicine5.9%
- Multiple Myeloma Research and TreatmentsMedicine5.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Hematology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 19.41LetPub ·
- Impact factor (publisher)
- 20.4Publisher website ·
- CiteScore 2026-06
- 29.4LetPub ·
- CiteScore (publisher)
- 29.4Publisher website ·
- SJR 2026-06
- 6.9LetPub ·
- SNIP 2026-06
- 5.5LetPub ·
- h-index
- 33LetPub ·
- h-index
- 134OpenAlex ·
- i10-index
- 703OpenAlex ·
- 2-year mean citedness
- 7.08OpenAlex ·
- Self-citation rate
- 2%LetPub ·
- Share of gold OA articles
- 11.88%LetPub ·
Volume
- Articles per year
- 69LetPub ·
Articles by year OpenAlex count · 2,032 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 124 | 18 | 81 |
| 2025 | 177 | 54 | 913 |
| 2024 | 195 | 56 | 2,519 |
| 2023 | 209 | 63 | 5,140 |
| 2022 | 207 | 66 | 5,303 |
| 2021 | 199 | 73 | 6,030 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
70 daysMedian, submission to acceptance · P25–P75 39 days – 92 days
- Acceptance to online
- median 63 days (30 articles)
- Submission to online
- median 128 days
- Sample
- 77 articles with submission and acceptance dates (339 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 6 daysPublisher website ·
- First decision after review
- 44 daysPublisher website ·
- Submission to acceptance
- 87 daysPublisher website ·
- Acceptance to publication
- 60 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 7,280 / EUR 6,810 / GBP 5,830 / JPY 902,940 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lancet Publishing Group
- Country or region
- ENGLAND
- Language
- English
- ISSN
- 2352-3026
- Print ISSN
- 2451-9960
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Lancet Haematology
What CAS zone is Lancet Haematology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Lancet Haematology is in Zone 1 of Medicine, and in Zone 1 of the minor category Hematology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Lancet Haematology?
The latest impact factor listed by LetPub is 19.41; CiteScore 29.4, h-index 134.
How long does peer review take at Lancet Haematology?
Based on the dates recorded on 77 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 70 days (interquartile range 39–92 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Lancet Haematology?
According to LetPub and DOAJ records, Lancet Haematology is indexed in SCIE and Scopus.
Is Lancet Haematology open access, and what is the APC?
Lancet Haematology is a hybrid journal. For open-access publication: APC about USD 7,280.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .